Common Variable Immunodeficiency — Research Summary
Printed from RareWays (rareways.com.au) on 10 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Pulmonary embolism and aseptic meningitis complicating IVIG for common variable immunodeficiency syndrome.
Butz Daniel et al. — The journal of allergy and clinical immunology. Global (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41883426/
- 2.
Immune-related enteropathy.
Butler Kimberley et al. — Current opinion in gastroenterology (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41782401/
- 3.
NF-κB1 haploinsufficiency due to a novel c.104delT variant in two patients with common variable immunodeficiency.
Bylica Jan et al. — Clinical immunology (Orlando, Fla.) (30 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41921718/
- 4.
Heterozygous NFKB1 variant causes inflammatory dysregulation shaped by broader genetic context in common variable immunodeficiency.
Hayes Kevin M et al. — JCI insight (23 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41869721/
- 5.
Improving clinical risk stratification in CVID: The importance of robust statistical testing and accurate event reporting.
Wang Jice — The Journal of allergy and clinical immunology (20 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41860512/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Common Variable Immunodeficiency
Common Variable Immunodeficiency is the most common symptomatic primary antibody deficiency, characterised by low immunoglobulin levels, poor vaccine responses, and increased susceptibility to recurrent infections. It is typically diagnosed in the second or third decade of life. Treatment requires regular immunoglobulin replacement therapy.
Most Recent Research
This case highlights the importance of vigilance for both thrombotic and inflammatory adverse events in patients with common variable immunodeficiency who are receiving intravenous immunoglobulin. It demonstrates that a multifaceted approach, including altering the product, infusion rate, and premedication, can effectively manage these complex complications.
Common Questions
What is Common Variable Immunodeficiency?
Common Variable Immunodeficiency is the most common symptomatic primary antibody deficiency, characterised by low immunoglobulin levels, poor vaccine responses, and increased susceptibility to recurrent infections. It is typically diagnosed in the second or third decade of life. Treatment requires regular immunoglobulin replacement therapy.
How many clinical trials are available for Common Variable Immunodeficiency?
RareWays currently indexes 47 clinical trials for Common Variable Immunodeficiency, of which 9 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Common Variable Immunodeficiency come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Common Variable Immunodeficiency.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.